AtriCure Completes Enrollment in Landmark 6,500-Patient LeAAPS Trial for Stroke Prevention
核心洞察
AtriCure has completed enrollment of 6,500 patients across 137 global centers in the LeAAPS clinical trial, marking the largest cardiac surgery device trial ever conducted.
The prospective, randomized, blinded superiority trial evaluates the AtriClip LAA Exclusion System (搜索) for preventing ischemic stroke (搜索) in cardiac surgery patients without prior atrial fibrillation (搜索) history.
The trial targets a large underserved population of over one million annual cardiac surgery patients, with more than 70% having no preoperative atrial fibrillation (搜索) diagnosis.
AtriCure has achieved a significant milestone in cardiovascular device research by completing enrollment in the LeAAPS (left atrial appendage (搜索) exclusion for prophylactic stroke reduction) clinical trial, enrolling 6,500 patients across 137 centers globally. This landmark study represents the largest cardiac surgery device trial ever conducted and evaluates the stroke reduction benefits of AtriClip devices in cardiac surgery patients without a preoperative atrial fibrillation (搜索) diagnosis.
Trial Design and Patient Population
The LeAAPS trial (NCT05478304) is a prospective, randomized, blinded, superiority, investigational device exemption (IDE) trial that began enrollment in January 2023. The study evaluates the AtriClip LAA Exclusion System (搜索) for preventing ischemic stroke (搜索) and systemic arterial embolism (搜索) in a large and often underserved patient population at elevated risk for these events.
The trial targets cardiac surgery patients without a history of atrial fibrillation (搜索), representing a substantial clinical opportunity. According to AtriCure, well over one million cardiac surgery procedures occur annually worldwide, with more than 70% of these patients having no history of atrial fibrillation before surgery.
Clinical Significance and Market Impact
"The LeAAPS trial is a bold clinical evidence initiative that demonstrates AtriCure's unwavering commitment to improving care for cardiac surgery patients," said Michael Carrel, President and CEO of AtriCure. "The rapid pace of trial enrollment is a testament to the exceptional team of clinical trial investigators and broader clinician interest in changing the standard of care in cardiac surgery."
The study addresses a long-standing clinical question in cardiovascular medicine. "For decades, the medical community has sought to better understand the role of the LAA in stroke following cardiac surgery," said Dr. Richard Whitlock, Cardiothoracic Surgeon at McMaster University and Global Principal Investigator for the trial. "LeAAPS aims to deliver definitive evidence to guide optimal care for high-risk patients without Afib who may benefit from LAA exclusion."
Regulatory and Commercial Implications
AtriCure first entered the left atrial appendage (搜索) management market with FDA 510(k) clearance of the AtriClip System in 2010. Today, AtriClip devices are the most widely used LAA management device worldwide. The company plans to use LeAAPS data to support an expanded indication for stroke prevention in patients at elevated risk of ischemic stroke (搜索).
Results from the LeAAPS trial are expected to inform clinical practice and treatment guidelines for stroke prevention using AtriClip platform technology in patients undergoing planned cardiac surgery. The trial will continue with five years of follow-up to assess long-term outcomes.
Research Collaboration
LeAAPS is being conducted in collaboration with the Population Health Research Institute (PHRI), affiliated with McMaster University in Hamilton, Ontario. PHRI brings extensive experience in designing and executing large-scale international clinical trials, lending additional credibility to the study design and execution.
Company Background
AtriCure provides innovative technologies for the treatment of atrial fibrillation (搜索) and related conditions, affecting more than 59 million people worldwide. The company's product portfolio includes the Isolator Synergy Ablation System (搜索), which is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent atrial fibrillation, and the AtriClip Left Atrial Appendage (搜索) Exclusion System products, which are the most widely sold LAA management devices worldwide.